Knowledge Centre
Learn about gastrointestinal conditions.
- Home
- Company
- Naronapride (ATI-7505)
- Knowledge Centre
-
News
-
Press
>
- Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
- Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
- Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
- Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
- Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
-
Press
>
- Contact
Copyright RENEXXION IRELAND LTD 2023. All rights reserved.
- Home
- Company
- Naronapride (ATI-7505)
- Knowledge Centre
-
News
-
Press
>
- Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
- Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
- Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
- Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
- Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
-
Press
>
- Contact